Skip to main content

RA Capital Management — Portfolio, Page 9

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
20
Industries
Biotechnology 21Health Care 14Pharmaceutical 11Therapeutics 10Life Science 5Biopharma 5+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 193216 of 453
Wave Life Sciences
December 2025

Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases

Biotechnology · Boston$350.0M Post-IPO Equity
Nautilus Biotechnology
January 2026

Nautilus Biotechnology is a life sciences company that develops a platform for analyzing and quantifying the human proteome.

Biotechnology · San Carlos$1.6M Grant
89bio
January 2025

89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.

Biopharma · San Francisco$287.5M Post-IPO Equity
Emergence Therapeutics
December 2021

Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.

Biotechnology · Duisburg$98.1M Series A
MARS
December 2024

MARS provides digital financial services with unique card options and rewards programs.

Banking · Besiktas$2.8M Seed
Tourmaline Bio
January 2024

Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.

Biotechnology · New York$172.5M Post-IPO Equity
Protara Therapeutics
December 2025

Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options.

Biotechnology · New York$75.0M Post-IPO Equity
Triana Biomedicines
December 2025

Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease.

Biopharma · Lexington$120.0M Series B
Janux Therapeutics
December 2024

Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.

Biotechnology · La Jolla$350.0M Post-IPO Equity
Pardes Biosciences
December 2021

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.

Biotechnology · Carlsbad$75.0M Post-IPO Equity
TScan Therapeutics
December 2024

TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.

Biotechnology · Waltham$30.0M Post-IPO Equity
NTx
December 2025

Nature’s Toolbox is a biotechnology company that provides a proprietary host-independent biological manufacturing and development platform.

Biotechnology · Rio Rancho$10.0M Venture - Series Unknown
Third Harmonic Bio
January 2025

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.

Biotechnology · Cambridge$3.9M Post-IPO Equity
Ambros Therapeutics
December 2025

Ambros Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Irvine$125.0M Series A
Nodexus
December 2021

Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.

Biopharma · San Jose$30.0M Series A
Tasso
December 2021

Tasso is a Medical innovation company changing the way diagnostics are delivered

Health Care · Seattle$100.0M Series B
Global Blood Therapeutics
December 2021

GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.

Biotechnology · South San Francisco$300.0M Post-IPO Debt
BioAge Labs
January 2026

BioAge Labs is a clinical-stage biotechnology company that develops therapeutics to treat obesity and metabolic diseases.

Biopharma · Richmond$115.0M Post-IPO Equity
Belite Bio
December 2025

Belite Bio is a clinical stage biopharmaceutical drug development company.

Biotechnology · San Diego$350.0M Post-IPO Equity
CG Oncology
December 2024

CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.

Biotechnology · Irvine$238.0M Post-IPO Equity
Curie Therapeutics
December 2021

Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.

Health Care · Boston$75.0M Series A
Tenaya Therapeutics
December 2025

Tenaya Therapeutics a clinical-stage biotechnology company that develops novel therapies to treat heart diseases.

Biopharma · San Francisco$60.0M Post-IPO Equity
New Amsterdam Pharma
December 2024

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Biotechnology · Naarden$452.6M Post-IPO Equity
Rivus Pharmaceuticals
January 2025

Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.

Biotechnology · Charlottesville$57.0M Venture - Series Unknown

Where RA Capital Management invests

Biotechnology21
Health Care14
Pharmaceutical11
Therapeutics10
Life Science5
Biopharma5

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Life Science. The firm invests across 20 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Wave Life Sciences, Nautilus Biotechnology, 89bio, Emergence Therapeutics, MARS. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →